Novo Nordisk Operating Income 2010-2023 | NVO

Novo Nordisk annual/quarterly operating income history and growth rate from 2010 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Novo Nordisk operating income for the quarter ending December 31, 2023 was $3.871B, a 65.09% increase year-over-year.
  • Novo Nordisk operating income for the twelve months ending December 31, 2023 was $14.894B, a 40.6% increase year-over-year.
  • Novo Nordisk annual operating income for 2023 was $14.894B, a 40.6% increase from 2022.
  • Novo Nordisk annual operating income for 2022 was $10.593B, a 13.53% increase from 2021.
  • Novo Nordisk annual operating income for 2021 was $9.33B, a 12.52% increase from 2020.
Novo Nordisk Annual Operating Income
(Millions of US $)
2023 $14,894
2022 $10,593
2021 $9,330
2020 $8,292
2019 $7,867
2018 $7,224
2017 $7,438
2016 $7,197
2015 $7,357
2014 $6,150
2013 $5,609
2012 $5,093
2011 $4,182
2010 $3,368
2009 $2,669
Novo Nordisk Quarterly Operating Income
(Millions of US $)
2023-12-31 $3,871
2023-09-30 $3,929
2023-06-30 $3,490
2023-03-31 $3,604
2022-12-31 $2,345
2022-09-30 $2,731
2022-06-30 $2,630
2022-03-31 $2,887
2021-12-31 $2,088
2021-09-30 $2,418
2021-06-30 $2,396
2021-03-31 $2,429
2020-12-31 $1,830
2020-09-30 $2,011
2020-06-30 $2,044
2020-03-31 $2,408
2019-12-31 $1,749
2019-09-30 $1,925
2019-06-30 $2,026
2019-03-31 $2,167
2018-12-31 $1,372
2018-09-30 $1,843
2018-06-30 $1,954
2018-03-31 $2,055
2017-12-31 $1,621
2017-09-30 $1,903
2017-06-30 $1,980
2017-03-31 $1,934
2016-12-31 $1,615
2016-09-30 $1,863
2016-06-30 $1,898
2016-03-31 $1,821
2015-12-31 $1,620
2015-09-30 $1,786
2015-06-30 $1,850
2015-03-31 $2,101
2014-12-31 $1,544
2014-09-30 $1,525
2014-06-30 $1,605
2014-03-31 $1,476
2013-12-31 $1,346
2013-09-30 $1,419
2013-06-30 $1,504
2013-03-31 $1,339
2012-12-31 $1,323
2012-09-30 $1,322
2012-06-30 $1,322
2012-03-31 $1,126
2011-12-31 $1,063
2011-09-30 $998
2011-06-30 $997
2011-03-31 $994
2010-12-31 $906
2010-09-30 $1,077
2010-06-30 $924
2010-03-31 $681
2009-12-31 $532
2009-09-30 $806
2009-06-30 $749
2009-03-31 $687
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $557.486B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $743.143B 123.75
Johnson & Johnson (JNJ) United States $390.509B 15.54
Merck (MRK) United States $321.544B 84.64
AbbVie (ABBV) United States $316.040B 16.10
Novartis AG (NVS) Switzerland $216.326B 14.99
AstraZeneca (AZN) United Kingdom $200.284B 17.75
Pfizer (PFE) United States $150.148B 14.53
Sanofi (SNY) $119.624B 10.77
Innoviva (INVA) United States $0.977B 6.80